Brazil confirms first case of deadlier mpox Clade 1b variant

São Paulo confirmed on Friday what public health officials had been watching for: Brazil's first case of Clade 1b, the more lethal variant of mpox that has been driving a major outbreak in the Democratic Republic of Congo. The patient is a 29-year-old woman living in the São Paulo metropolitan area who is recovering well and expected to leave the hospital within days. She had not traveled to outbreak zones but had recently received visitors from the DRC, her country of origin.

The arrival of Clade 1b in Brazil marks a shift in the epidemiology of a disease that seemed, for a moment in 2022 and 2023, to be fading from global attention. That earlier outbreak, caused by a milder variant called Clade 2b, spread rapidly through sexual networks and infected hundreds of thousands of people worldwide. Brazil was hit hard—it was the first country outside Africa to report a death. But Clade 2b carried a fatality rate of roughly one percent. Clade 1b is different. Estimates place its lethality at around ten percent, making it ten times deadlier than the strain that dominated the 2022 pandemic.

The World Health Organization declared a global health emergency in August of last year, largely because of Clade 1b's emergence and spread. The variant was first detected by researchers in September 2023, a new mutation derived from the Central African lineage of mpox—the strain that had circulated in Congo for decades before the world took notice. What alarmed epidemiologists was not just its severity but evidence that it had acquired the ability to transmit through sexual contact, the same evolutionary advantage that allowed Clade 2b to circle the globe.

Geographically, Clade 1b now has community transmission—meaning sustained local spread rather than isolated imported cases—in six African countries: the DRC, Burundi, Kenya, Rwanda, Uganda, and Zambia. The DRC remains the epicenter, with large numbers of deaths, though no fatalities from Clade 1b have been reported in any country outside Africa so far. Beyond the continent, fourteen nations have now documented cases: the United Kingdom with nine, China and Germany with seven each, Thailand with four, and single cases scattered across Belgium, the United States, Canada, France, India, Oman, Pakistan, Sweden, and the United Arab Emirates. Most of these are imported cases—travelers who contracted the virus during their incubation period or in early symptomatic stages and were diagnosed after arrival.

The mechanics of transmission remain consistent with what was learned during the 2022 outbreak. Mpox spreads through direct physical contact with an infected person, contaminated materials, or infected animals. The virus causes fever, muscle aches, fatigue, and swollen lymph nodes, followed by a characteristic rash of fluid-filled lesions that typically begin on the face and spread downward, though in sexually transmitted cases they appear in the genital region. Symptoms emerge between six and thirteen days after exposure, though they can take up to three weeks to manifest. Most cases resolve on their own within two to three weeks.

What keeps the WHO's emergency declaration in place is not the handful of cases outside Africa but the trajectory and the obstacles to containment. In late February, the WHO's Emergency Committee for mpox met and recommended that the organization maintain its highest alert level. The committee cited three persistent concerns: the continuous rise in case numbers, the geographic expansion of the virus, the ongoing violence in eastern Congo that hampers outbreak response efforts, and critically, the lack of sufficient funding to implement containment strategies. Richard Hatchett, executive director of the Coalition for Epidemic Preparedness Innovations, framed the risk starkly in an interview: the world is watching a potentially catastrophic scenario unfold—a virus ten times deadlier than the 2022 strain that has now found its way into sexual transmission networks, the same networks that allowed the milder variant to become a global pandemic.

Vaccines developed for smallpox, which was eradicated in 1980, offer protection against mpox and are already being deployed in Brazil to high-risk groups, including people living with HIV who have low CD4 counts. But vaccination campaigns require resources, coordination, and time—luxuries in short supply in the DRC and increasingly scarce as the virus spreads. The Brazilian patient's recovery is reassuring. It is not, however, the end of the story.